Skip to main content

Table 2 Regulation of the 52 most frequently detected miRNAs in CSF of patients with dementia

From: miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study

miRNA NAD Ncontrol MAD (range) Mcontrol (range) FC p
miR-15a-5p 10 10 1.20 (0.63–4.22) 0.83 (0.52–1.01) 1.44 0.005
miR-29c-3p 10 10 0.81 (0.47–1.55) 1.33 (0.75–1.78) 0.60 0.009
let-7i-5p 10 10 1.31 (0.67–3.23) 0.85 (0.27–1.27) 1.54 0.019
miR-22-3p 10 9 0.83 (0.20–1.75) 1.35 (0.83–2.01) 0.62 n.s.
miR-24-3p 9 10 0.91 (0.19–1.23) 1.17 (0.81–1.94) 0.78 n.s.
miR-185-5p 10 9 1.35 (0.39–5.13) 0.62 (0.30–1.45) 2.16 n.s.
miR-27b-3p 10 10 0.95 (0.49–1.48) 1.21 (0.63–1.87) 0.78 n.s.
miR-142-3p 9 9 1.19 (0.27–4.31) 0.86 (0.26–1.83) 1.38 n.s.
let-7 g-5p 10 10 1.09 (0.55–2.75) 0.79 (0.39–2.19) 1.37 n.s.
miR-23a-3p 10 10 0.92 (0.53–1.55) 1.11 (0.62–2.04) 0.82 n.s.
miR-23b-3p 10 10 1.00 (0.38–1.24) 1.05 (0.60–2.55) 0.94 n.s.
miR-130a-3p 10 10 0.82 (0.41–1.56) 1.22 (0.42–2.13) 0.67 n.s.
let-7c-5p 10 10 0.88 (0.37–2.21) 1.15 (0.35–3.09) 0.76 n.s.
miR-150-5p 10 9 0.89 (0.23–5.44) 0.82 (0.37–1.68) 1.09 n.s.
miR-361-5p 9 9 0.95 (0.47–1.32) 1.00 (0.70–1.51) 0.94 n.s.
miR-25-3p 10 9 1.00 (0.36–5.49) 0.87 (0.34–1.77) 1.14 n.s.
miR-221-3p 10 10 1.68 (0.15–3.04) 1.22 (0.15–1.70) 1.38 n.s.
miR-29a-3p 10 10 0.96 (0.72–1.30) 1.01 (0.71–1.71) 0.94 n.s.
miR-30a-5p 10 10 1.32 (0.20–2.91) 1.12 (0.37–1.91) 1.17 n.s.
miR-10b-5p 9 10 0.90 (0.26–5.08) 1.04 (0.21–1.70) 0.86 n.s.
let-7a-5p 10 10 0.80 (0.29–2.58) 1.14 (0.65–3.49) 0.70 n.s.
miR-125b-5p 10 10 0.85 (0.62–1.53) 0.98 (0.69–2.77) 0.87 n.s.
miR-16-5p 10 10 0.96 (0.05–9.45) 0.98 (0.56–1.47) 0.98 n.s.
miR-424-5p 10 10 1.19 (0.35–3.38) 0.72 (0.47–2.38) 1.65 n.s.
miR-143-3p 10 10 1.04 (0.45–1.48) 0.92 (0.69–2.32) 1.12 n.s.
miR-19a-3p 9 10 1.14 (0.21–3.68) 1.15 (0.65–1.49) 0.99 n.s.
miR-124-3p 10 9 1.31 (0.26–2.73) 1.21 (0.32–2.08) 1.08 n.s.
let-7b-5p 10 10 1.03 (0.31–3.50) 0.83 (0.45–3.39) 1.23 n.s.
miR-146a-5p 9 10 1.37 (0.23–2.40) 0.91 (0.20–2.69) 1.50 n.s.
let-7d-3p 9 10 1.02 (0.54–1.89) 1.33 (0.62–1.83) 0.76 n.s.
miR-125a-5p 10 9 1.21 (0.32–2.96) 0.71 (0.29–2.68) 1.69 n.s.
miR-27a-3p 9 10 1.14 (0.15–2.81) 1.29 (0.25–3.03) 0.88 n.s.
miR-30d-5p 10 10 1.16 (0.31–2.47) 1.15 (0.34–1.83) 1.01 n.s.
miR-99a-5p 10 10 0.98 (0.57–1.36) 1.07 (0.62–1.93) 0.91 n.s.
miR-145-5p 10 10 1.16 (0.30–1.73) 1.00 (0.47–2.05) 1.15 n.s.
miR-100-5p 10 10 0.92 (0.54–1.88) 1.07 (0.63–1.86) 0.85 n.s.
miR-223-3p 9 10 1.14 (0.86–2.74) 0.78 (0.22–4.81) 1.45 n.s.
miR-320a 10 10 0.94 (0.54–1.62) 1.05 (0.64–1.68) 0.90 n.s.
miR-497-5p 10 10 1.07 (0.51–1.72) 1.08 (0.64–1.81) 0.98 n.s.
miR-373-5p 9 10 1.10 (0.26–2.66) 1.11 (0.30–3.44) 0.98 n.s.
miR-204-5p 10 10 1.05 (0.07–2.30) 0.99 (0.47–2.28) 1.06 n.s.
miR-92a-3p 10 10 0.94 (0.70–3.69) 0.84 (0.47–2.17) 1.12 n.s.
miR-423-5p 10 10 1.11 (0.65–2.27) 0.78 (0.44–2.22) 1.42 n.s.
miR-19b-3p 10 10 1.08 (0.18–2.25) 1.20 (0.21–2.20) 0.90 n.s.
miR-9-5p 9 10 1.25 (0.50–1.97) 1.24 (0.24–3.11) 1.00 n.s.
miR-30c-5p 10 10 1.15 (0.20–2.57) 0.99 (0.37–2.38) 1.15 n.s.
miR-21-5p 10 10 0.89 (0.66–2.29) 1.06 (0.27–1.86) 0.83 n.s.
miR-34a-5p 10 9 0.99 (0.26–2.39) 1.06 (0.46–2.07) 0.94 n.s.
miR-101-3p 10 9 1.11 (0.37–1.48) 0.93 (0.56–2.64) 1.19 n.s.
miR-29b-3p 9 9 1.12 (0.31–1.76) 0.92 (0.49–2.02) 1.22 n.s.
miR-199a-3p 10 10 0.92 (0.58–3.40) 1.16 (0.39–1.67) 0.79 n.s.
miR-9-3p 10 10 1.13 (0.23–2.35) 1.02 (0.28–2.86) 1.09 n.s.
  1. N AD number of Alzheimer patients in which the miRNA was detected, N control number of control patients in which the miRNA was detected, M AD the median of relative expression levels among Alzheimer patients, M control median of relative expression levels among control patients, FC fold change of median values, p p-values of difference calculated by two-sided nonparametric Mann–Whitney test (not corrected for multiple testing), n.s. nonsignificant (p > 0.05)